New antibody weapon tested against tough childhood cancer
NCT ID NCT01757626
Summary
This study is testing whether a lab-made antibody called Hu3F8, given with an immune-boosting drug (GM-CSF), is safe and effective for treating high-risk neuroblastoma that has come back or resisted standard treatments. It involves about 186 patients, including children over 1 year old and adults, who have this aggressive cancer. The main goals are to find the safest dose and see if the combination can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.